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Summary
Hepatitis E virus (HEV) is emerging as a global public health
threat. Water-borne HEV outbreaks are common in develop-
ing countries and are associated with genotypes 1 and 2. In
industrialised countries, sporadic cases of zoonotic trans-
mission associated with genotypes 3 and 4 are increasingly
being reported. Transfusion- and transplantation-transmitted
HEV have been documented, although ingestion of contami-
nated food is thought to be the major transmission route.
Severe disease is possible and chronic hepatitis infection
occurs in solid-organ-transplant recipients and in patientswith
immunosuppressive disorders. In Australia, HEV cases are
mainly travellers returning from disease endemic countries.
Indeed, there are few reported cases of locally acquired HEV.
Pigs in Australia have been shown to be infected with HEV,
which indicates the possibility of zoonotic transmission. The
extent of locally acquired infection is not known, however it
may be greater than expected and may necessitate labora-
tory testing in patients reporting no overseas travel.
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INTRODUCTION
Hepatitis E virus (HEV) is a causative agent of acute hepatitis,1
originally known as enterically transmitted non-A, non-B
hepatitis virus, due to its faeco-oral transmission route.1–3 Such
a mode of transmission is common today in developing
countries, due to poor sanitation.1,2 Other routes of trans-
mission, such as through ingestion of contaminated food and
contact with infected animals, are increasingly being reported
in many industrialised countries.2–4 Cases of transfusion-trans-
mitted HEV have been reported from industrialised countries,
highlighting transfusion as one of the possible routes of trans-
mission.1–3 A recent study in the United Kingdom (UK) has
detected HEV RNA at a rate of one in just under 3000 blood
donations.1 The majority of HEV cases in developed countries
are in travellers returning from countries endemic for HEV;
however, autochthonous or locally acquired HEV is emerging
as a public health concern.3,4 In the majority of individuals,
infection with HEV is sub-clinical; however, more severe
infection is possible, with chronic infection observed in
solid-organ transplant recipients and in patients with immuno-
suppressive disorders.1,2
There are 4 genotypes of HEV (HEV 1–4), which differ in
epidemiological distribution, modes of transmission and patho-
genicity. HEV genotype 1 includes human strains reported from
Asia and Africa.2,5 Genotype 2 is also solely a human virus,
with strains occurring in Mexico and some African
countries.2,3,5 HEV genotype 3 and 4, the former being globally
ubiquitous and the latter restricted to south-east Asia, infect
both humans and swine.2,3,5 Genotypes 1 and 2 are associated
with the faeco-oral transmission route, predominantly in devel-
oping countries,4 whereas genotypes 3 and 4 are related to
sporadic cases of zoonotic transmission in humans, particularly
through the consumption of infected pork or contact with
infected animals, and tend to occur in developed countries.2,5
HEV-3 RNA has been detected in pigs’ livers sold in grocery
stores in the United States (US) the UK, France and
Germany.4,6,7 A higher HEV seroprevalence among pig farm
workers compared to the general population supports contact as
a possible mode of transmission.5 Genotypes 1 and 2 result in
self-limiting hepatitis in young adults, with increased mortality
seen in pregnant women and immunocompromised patients.2,4
Genotypes 3 and 4 can cause clinically apparent hepatitis in
middle-aged and older individuals.4 Such differences in clinical
outcomes with genotypes are not well understood.4
CLINICAL FEATURES
Acute hepatitis caused by HEV resembles that caused by other
hepatotropic viruses [hepatitis A virus (HAV), hepatitis B virus
(HBV), hepatitis C virus (HCV), Epstein–Barr virus or cyto-
megalovirus], or due to drug induced liver injury (DILI).4 The
average incubation period is 30–40 days (range 2–9 weeks),3
with the majority of HEV infections being asymptomatic
(67–93%).2,8 Features of symptomatic infections include anor-
exia, epigastric pain, discoloured urine, nausea, vomiting,
diarrhoea, fever, jaundice, elevation of serum transaminase
and hepatomegaly.9,10 During outbreaks in developing
countries, a case fatality rate of 0.5–4% has been reported.2,5
A higher mortality rate of 8–11% in non-endemic countries is
possibly due to infection in individuals with pre-existing liver
disease.3 Incidence of disease and fulminant hepatitis is even
higher in pregnant women during the third trimester.2 Mortality
in pregnancy also varies with geographical region, and reaches
10–25% in developing countries.2,4 Chronic HEV infection
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refers to a condition following the acute phase, in which HEV
replication persists for more than 3 months.11 Cases of chronic
HEV infection have been documented in solid-organ transplant
(kidney, liver and pancreas) recipients,11 and in immunosup-
pressive conditions like infection with human immunodefi-
ciency virus.12 Only genotype 3 has been shown to be involved
in chronic infections.11 Non-hepatic manifestations of HEV can
include pancreatitis, haematological manifestations (thrombo-
cytopenia, haemolysis) or neurological syndromes (Guillain–
Barre syndrome, meningoencephalitis, pseudotumour cerebri,
nerve palsies).2,9
PATHOGENESIS
HEV is difficult to culture in cell lines, therefore its pathogen-
esis and method of replication are not well understood.13,14 It is
assumed that when the virus is faeco-orally transmitted, it
replicates in the intestinal cells and reaches the liver through
the portal vein.13 The virus attaches to hepatocytes through the
binding of truncated peptide p239 to heparin sulphate proteo-
glycans on the cell wall, and enters the target cell by endocy-
tosis.13,15 The virus has three open reading frames (ORFs):
ORF1 encodes for non-structural proteins (such as RNA depen-
dent RNA polymerase, methyltransferase, and RNA heli-
case);13,16 ORF2 encodes for the viral capsid;2,16 and ORF3
encodes phosphoproteins involved in viral morphogenesis and
release.2,13,16 Both viral (such as the infecting genotype and
infectious dose)4,13 and host factors (including age, pre-existing
hepatic disease, pregnancy)2–4,13 influence the severity of
disease.
TREATMENT AND PREVENTION
Acute cases of HEV that are self-limiting do not require
treatment.4,9 Management of chronic cases of HEV includes
treatment with ribavirin for 3 months, used alone or in com-
bination with pegylated interferon-a.2 Ribavirin is contraindi-
cated during pregnancy, and use of interferon increases risk of
organ rejection in transplant recipients.2,4
Two HEV vaccines are in development, however neither is
licensed worldwide.2 The first is a recombinant vaccine encod-
ing ORF2 of a Pakistani HEV strain made using a baculovirus
system in an insect (Spodoptera frugiperda, Sf9) cell line.17 A
Phase I clinical trial of this vaccine (produced by DynCorp,
USA) was conducted at the Walter Reed Army Institute of
Research and was determined to be safe and immunogenic, but
in need of further evaluation.17 A Phase II trial of the vaccine
was performed with the Nepalese Army, and efficacy of three
doses of vaccine was found to be 95.5% effective, with unclear
information on durability of immunity.2,3 A second vaccine
referred to as HEV 239, is based on a recombinant protein of
ORF2 (HEV genotype 1) produced in an Escherichia coli
expression system.2 A clinical Phase II trial conducted in China
determined this prototype vaccine was safe and immunogenic.2
A Phase III trial of HEV 239 (Hecolin; Xiamen Innovax
Biotech, China) determined an efficacy of 100%.18 This
vaccine has recently been approved in China2 where its use
is focussed on high-risk populations, such as women of child-
bearing-age, chronic liver disease patients and food industry
workers.19 In developed countries where genotypes 3 and 4 are
present, this vaccine may be considered for certain patients,
such as organ transplant recipients or those with chronic liver
disease.20 However, this vaccine is not licensed worldwide.
Passive immunisation with immunoglobulin preparations in
animal studies has been shown to be effective;10 however,
immunoprophylaxis with low titre human serum immunoglo-
bulin has not been successful in humans.10 Monoclonal anti-
bodies against HEV for humans has not been tested.10
MARKERS OF INFECTION AND DIAGNOSIS
Acute HEV infection is characterised by an increase in
bilirubin, alanine aminotransferase and aspartate aminotrans-
ferase.21 HEVRNA in blood and stool appears at the same time,
2–3 weeks after infection.2,3 Viraemia persists for up to
4 weeks, however can last longer in some individuals, whereas
virus in stools is detectable up to 6 weeks.1–3 HEV IgM is
detectable 3–4 weeks after exposure and persists for
6 months.2,3 HEV IgG is detectable 4–5 weeks post infection,
and persists for 12 or more years.2,3
HEV cases are diagnosed based on the detection of the viral
RNA and serological markers (HEV IgM, high or rising titre of
HEV IgG).21 Liver biopsy for HEV diagnosis is not required,
due to its course as a self-limiting illness.3 Histological exam-
ination of a liver with hepatitis E infection is similar to other
causes of acute hepatitis, with lobular disarray with reticulin
framework distortion.3 The portal tracts are infiltrated with
lymphocytes, plasma cells and polymorphs including eosino-
phils.3,22 In HEV infected patients with underlying cirrhosis,
liver biopsy resembles that of alcoholic hepatitis and therefore
is non-specific.3
A recent study in southeastern Scotland in acute hepatitis
patients has shown that HEV infection is more common than
HAV, HBV and HCV.23 This study recommended that HEV
screening be introduced in the initial testing panel for acute
hepatitis.23 There is a possibility that patients with non-A, non-
B, non-C hepatitis may be mis-diagnosed with non-viral related
disease, such as DILI or alcohol consumption. This further
necessitates testing for HEV infection markers in acute
hepatitis patients.
In Australia, HEV infection is nationally notifiable and
confirmed cases are notified based on laboratory definitive
evidence or laboratory suggestive evidence with clinical and
epidemiological evidence (travel to a HEV endemic country
15–64 days prior to onset or a link to confirmed case).24
Laboratory definitive evidence is referred to as: detection of
HEV RNA by nucleic acid testing; HEV detection by electron
microscopy in faeces; or IgG seroconversion (an increase in
IgG antibody titre). Laboratory suggestive evidence refers to
detection of HEV IgM or IgG.24 In Australia, the most common
viral causes of acute hepatitis are HAV, HBV and HCV.25
Hence, the testing algorithm for laboratory diagnosis includes
testing for infection markers for these viruses only. HEV testing
is considered for acute hepatitis patients with recent overseas
travel history. However, in the absence of HEV testing for
patients with no overseas travel history, it is possible that HEV
infection may be missed, or misdiagnosed (as non-A, non-B,
non-C hepatitis, DILI or alcohol-induced hepatitis).3
GLOBAL EPIDEMIOLOGY
The global annual disease burden for HEV genotypes 1 and 2 in
2005 was estimated to be 20.1 million incident infections
resulting in 3.4 million symptomatic cases, 70,000 deaths
and 3000 still births.26 The study model represented 71%
of the world’s population with incidence rates greater for
younger individuals (aged 15–20 years).26 The burden for
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HEV genotypes 3 and 4 is not known. HEV seroprevalence
ranges from less than 5% to 52.5% in different countries.2
HEV EPIDEMIOLOGY IN AUSTRALIA
Data from the Commonwealth Department of Health indicates
there were 378 HEV notified cases from 1999 to 2013, with an
average of 25 cases per year (Fig. 1).27 Higher numbers of cases
were reported from New South Wales and Victoria. Most cases
are associated with travel to HEV endemic countries, mostly
Asia,28 and few cases are reported to be locally acquired. The
true incidence of HEV and exposure status of the Australian
population, however, is unknown due to its subclinical nature.
A seroprevalence study of HEV in 1995 among selected
groups determined HEV IgG prevalence of 0.4% in blood
donors, 2.2% in travellers and 7.7% in non-A, non-B, non-C
hepatitis patients as well as refugees.29 Retrospective study of
stored sera from patients in the 1970s (non-A, non-B hepatitis)
have shown serological evidence of HEV IgG.30 Our recent
study among a cohort of Australian blood donors has demon-
strated HEV seroprevalence of 5.9%.31
HEV in animals
Chandler et al. report HEV IgG seroprevalence to be 17% in
wild caught pigs and 30–95% in commercially raised pigs.32
This study used an in-house assay with unknown sensitivity and
specificity.32 Transmission from pigs to humans is possible
through ingesting infected undercooked meat or contact with
infected animals. An avian HEV strain associated with big liver
and spleen disease in chickens was identified in Australia in
1980.33 However, avian strains are not known to be transmitted
to humans.16
Locally acquired infection in humans
There are limited data on the extent of locally acquired HEV in
Australia and therefore the burden of autochthonous HEV
requires investigation. The first case of locally acquired
HEV infection was reported in 1995 from the Northern Ter-
ritory.34 The source of infection in this patient was not known.34
A case each in Victoria and Queensland were also notified as
being locally acquired in 2005,35 however neither case has been
published in peer reviewed journals. At least five other HEV
cases have recently been reported in New South Wales, all with
no recent overseas travel history and likely to be linked to the
consumption of undercooked pork liver sausages.36,37 Our
recent study in blood donors has reported an HEV seropreva-
lence of 3.37% in donors with no previous history of overseas
travel (Table 1). Of these donors, 57% were males and 64%
were >45 years of age. Demonstration of HEV serological
markers in such donors who reported no international travel
suggests the possibility of their infection being acquired within
Australia. HEV seroprevalence in Australian pig herds shown
in 199932 suggests that zoonotic transmission may be possible.
Other modes of transmission such as congenital, transfusion
and organ transplant have been documented overseas,1,2,5
which could contribute to the occurrence of locally acquired
infection, and associated risks therefore need to be assessed.
CONCLUSION
There is increasing public health concern in relation to HEV
globally, and specifically among many industrialised countries
traditionally considered non-endemic. Given this, there is a
need for increased awareness in relation to this emerging virus
in these countries, which include Australia. This awareness is
required at the level of public health authorities, in the clinical
settings and also with the general public. HEV is preventable
through the control of the source of infection, which includes
maintenance of a safe supply of drinking water, and prevention
of human-to-human, and animal-to-human transmission by
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Fig. 1 HEV notiﬁed cases in Australia from 1999–2013, by year (A) and age
group (B).27
Table 1 HEV IgG seroprevalence in a cohort of Australian blood donors
reporting no overseas travel (based on re-analysis of data from our previous
study31)
Donors
tested
Number
reactive
Prevalence,
% (95% CI)
Total 416 14 3.37 (1.63–5.10)
Gender
Female 180 6 3.33 (0.71–5.96)
Male 236 8 3.39 (1.08–5.70)
Age, years
<45 254 5 1.97 (0.26–3.68)
45 162 9 5.56 (2.03–9.08)
State/Territory
Australian Capital Territory 22 – –
New South Wales 61 5 –
Northern Territory 30 2 –
Queensland 75 1 –
South Australia 66 4 –
Tasmania 104 2 –
Victoria 30 – –
Western Australia 28 – –
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maintenance of personal hygiene and proper handling/cooking
of food. While the occurrence of travel-associated HEV infec-
tion in Australia is well known, there is limited knowledge of
the scale of locally acquired HEV in Australia and this needs
further investigation. It is likely that autochthonous trans-
mission will be greater than expected, and may necessitate
laboratory testing in patients reporting no overseas travel.
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